惡性星狀細胞瘤術後放療或合併放化療治療結果之比較 - Elsevier

惡性星狀細胞瘤的病人，存活率在放療這組為8.7%，放化療這組為67.9%（p值＝0.001）。

多形惡性神經膠質瘤的病人，存活率在放療這組為16.3%，放化療這組為 ... 跳至主導覽 跳至搜尋 跳過主要內容 ComparisonofTreatmentResultsofMalignantAstrocytomaafterpost-opRadiotherapyAloneorpost-opConcurrentChemoradiotherapyplusAdjuvantchemotherapy-ExperienceinTSGH貢獻的翻譯標題:惡性星狀細胞瘤術後放療或合併放化療治療結果之比較：三軍總醫院的經驗 Kuen-TzeLin,Ching-JungWu,Yee-MinJen,MeeiShyuanLee,Wen-YenHuang,Chang-MingChen,Hsing-LungChao,Chun-ShuLin,Yu-FuSu,Jang-ChunLin 研究成果:雜誌貢獻›文章›同行評審 總覽 指紋 摘要 目的：分析惡性星狀細胞瘤術後放療或合併放化療治療結果及預後因子。

材料及方法：從2002年4月至2007年12月，共有35位新診斷惡性星狀細胞瘤及多形惡性神經膠質瘤的病人接受手術切除，術後接受放射治療或同步放化療。

放射治療使用三度空間順形放射治療(3DCRT)，於六週內給予60Gy。

我們使用影像結合的技術，結合術前核磁共振及電腦斷層定位的影像，決定治療區域的範圍。

化學治療使用帝盟多，在同步放化療的過程，劑量為每天75mg/平方公尺，至少使用49天。

放療後化療，28天為一個療程，每個療程前5天接受化療，劑量為每天150-200mg/平方公尺，至少6個療程。

追蹤和存活時間的定義為切片診斷的日期到碼死亡的日期。

存活率曲線以Kaplan-Meier方法繪製。

結果：平均追蹤時間為19.1個月。

追蹤期間內，共10位病人存活，25位病人死亡。

所有病人的平均存活率為19.1個月。

三年存活率，在放療這組為14%，放化療這組為43%（p值＝0.002）。

三年無復發存活率，在放療這組為10.6%，放化療這組為13.9%（p值＝0.54）。

惡性星狀細胞瘤的病人，存活率在放療這組為8.7%，放化療這組為67.9%（p值＝0.001）。

多形惡性神經膠質瘤的病人，存活率在放療這組為16.3%，放化療這組為23.7%（p值＝0.261）。

放射治療照野內的復發為主要的復發型態。

所有35位病人中，有22位病人發生照野內復發(62.8%)。

所有的病人皆完成放射治療。

30位病人(86%)產生GradeI中樞神經毒性；5位病人(14%)產生GradeⅡ中樞神經毒性。

21位接受化療的病人中，18位病人在化療過程中並沒有任何副作用產生。

結論：對於新診斷的惡性星狀細胞瘤及多形惡性神經膠質瘤的病人手術切除後，術後接受同步放化療有統計學上存活率的幫助而僅有可接受之副作用。

貢獻的翻譯標題惡性星狀細胞瘤術後放療或合併放化療治療結果之比較：三軍總醫院的經驗原文英語頁（從-到）37-45頁數9期刊放射治療與腫瘤學卷18發行號1DOIshttps://doi.org/http://www.airitilibrary.com/Publication/alDetailedMesh?docid=1023988x-201103-201104160006-201104160006-37-45出版狀態已發佈-3月12011對外發佈是 Keywords惡性星狀細胞瘤多形惡性神經膠質瘤帝盟多放射治療同步放射化學治療順形放射治療 存取文件 http://www.airitilibrary.com/Publication/alDetailedMesh?docid=1023988x-201103-201104160006-201104160006-37-45 Astrocytoma Medicine&LifeSciences 100% Chemoradiotherapy Medicine&LifeSciences 96% AdjuvantChemotherapy Medicine&LifeSciences 91% Radiotherapy Medicine&LifeSciences 62% Temozolomide Medicine&LifeSciences 34% SurvivalRate Medicine&LifeSciences 26% Glioblastoma Medicine&LifeSciences 20% Therapeutics Medicine&LifeSciences 14% 引用此 APA Standard Harvard Vancouver Author BIBTEX RIS Lin,K-T.,Wu,C-J.,Jen,Y-M.,Lee,M.S.,Huang,W-Y.,Chen,C-M.,Chao,H-L.,Lin,C-S.,Su,Y-F.,&Lin,J-C.(2011).ComparisonofTreatmentResultsofMalignantAstrocytomaafterpost-opRadiotherapyAloneorpost-opConcurrentChemoradiotherapyplusAdjuvantchemotherapy-ExperienceinTSGH.放射治療與腫瘤學,18(1),37-45.https://doi.org/http://www.airitilibrary.com/Publication/alDetailedMesh?docid=1023988x-201103-201104160006-201104160006-37-45 ComparisonofTreatmentResultsofMalignantAstrocytomaafterpost-opRadiotherapyAloneorpost-opConcurrentChemoradiotherapyplusAdjuvantchemotherapy-ExperienceinTSGH./Lin,Kuen-Tze;Wu,Ching-Jung;Jen,Yee-Min;Lee,MeeiShyuan;Huang,Wen-Yen;Chen,Chang-Ming;Chao,Hsing-Lung;Lin,Chun-Shu;Su,Yu-Fu;Lin,Jang-Chun.於:放射治療與腫瘤學,卷18,編號1,01.03.2011,p.37-45.研究成果:雜誌貢獻›文章›同行評審 Lin,K-T,Wu,C-J,Jen,Y-M,Lee,MS,Huang,W-Y,Chen,C-M,Chao,H-L,Lin,C-S,Su,Y-F&Lin,J-C2011,'ComparisonofTreatmentResultsofMalignantAstrocytomaafterpost-opRadiotherapyAloneorpost-opConcurrentChemoradiotherapyplusAdjuvantchemotherapy-ExperienceinTSGH',放射治療與腫瘤學,卷18,編號1,頁37-45.https://doi.org/http://www.airitilibrary.com/Publication/alDetailedMesh?docid=1023988x-201103-201104160006-201104160006-37-45 LinK-T,WuC-J,JenY-M,LeeMS,HuangW-Y,ChenC-M等.ComparisonofTreatmentResultsofMalignantAstrocytomaafterpost-opRadiotherapyAloneorpost-opConcurrentChemoradiotherapyplusAdjuvantchemotherapy-ExperienceinTSGH.放射治療與腫瘤學.20113月1;18(1):37-45.https://doi.org/http://www.airitilibrary.com/Publication/alDetailedMesh?docid=1023988x-201103-201104160006-201104160006-37-45 Lin,Kuen-Tze;Wu,Ching-Jung;Jen,Yee-Min;Lee,MeeiShyuan;Huang,Wen-Yen;Chen,Chang-Ming;Chao,Hsing-Lung;Lin,Chun-Shu;Su,Yu-Fu;Lin,Jang-Chun./ComparisonofTreatmentResultsofMalignantAstrocytomaafterpost-opRadiotherapyAloneorpost-opConcurrentChemoradiotherapyplusAdjuvantchemotherapy-ExperienceinTSGH.於:放射治療與腫瘤學.2011;卷18,編號1.頁37-45. @article{bcd77bd04c3b478a8f9ce2f8a6be0c70,title="ComparisonofTreatmentResultsofMalignantAstrocytomaafterpost-opRadiotherapyAloneorpost-opConcurrentChemoradiotherapyplusAdjuvantchemotherapy-ExperienceinTSGH",abstract="Purpose:ToanalyzethetreatmentresultsofmalignantastrocytomaafterradiotherapyaloneorconcurrentchemoradiotherapyplusadjuvantchemotherapyinTSGH.MethodsandMaterials:FromApril2002toDecember2007,weidentified35patientswithdocumented,histologicallyconfirmed,previouslyuntreatedglioblastomamultiforme(GBM)oranaplasticastrocytoma(AA).Theyweretreatedwithsurgicalresectionfollowedbyradiotherapyaloneorchemoradiotherapyinourhospital.Atotalof60Gywasgivenin6weekswith3DconformalRT(3D-CRT).FusionofplanningCTwithMRIwasroutinelyusedtoassisttargetdelineation.Weusedconcomitanttemozolomide(75mg/m^2dailyupto49days)followedbyuptosixcyclesofadjuvanttemozolomide(150to200mg/m^2dailyforfivedays,every28days).Follow-upandsurvivaltimeswerecalculatedfromthedateofdiagnosistothedateoflastcontactordeath.Disease-freesurvival(DFS)andoverallsurvival(OS)werecomputedbyKaplan-Meiermethods.Results:Themedianfollow-upwas19.1months.Atthetimeofanalysis,10patientswerealive,25patientshaddied.Themediansurvivalratewas19.1monthsforallpatients.The3-yearoverallsurvivalrateswere14%and43%inradiotherapyalonearmandCCRTarm,respectively.(p=0.002).The3-yearprogression-freesurvivalrateswere10.6%and13.9%inradiotherapyaloneandCCRTarm,respectively.(p=0.54).IntheAAgroup,theoverallsurvivalrateswere8.7%and67.9%inradiotherapyalonearmandCCRTarm,respectively.(p=0.001).IntheGBMgroup,theoverallsurvivalrateswere16.3%and23.7%inradiotherapyaloneandCCRTarm,respectively.(p=0.261).In-fieldfailurewasthemajorcauseoffailure,among35patients,22(62.8%)patientshadin-fieldfailure.Allpatientscompletedradiotherapycourses.Thirty(86%)patientshadgrade1CNStoxicityand5(14%)patientshadgrade2CNStoxicity.Among21patientswhoreceivedtemozolomide,18patientshadnoobvioussideeffectsduringandafterchemotherapy.Conclusions:AdditionofadjuvantchemotherapywithtemozolomidetoradiotherapyforpatientswithnewlydiagnosedAAandGBMhasstatisticallysignificantsurvivalbenefitespeciallyforpatientsofAAwithtolerabletoxicity.",keywords="Anaplasticastrocytoma,Glioblastomamultiforme,Temozolomide,Radiotherapy,Chemoradiotherapy,Conformalradiationtherapy,惡性星狀細胞瘤,多形惡性神經膠質瘤,帝盟多,放射治療,同步放射化學治療,順形放射治療",author="Kuen-TzeLinandChing-JungWuandYee-MinJenandLee,{MeeiShyuan}andWen-YenHuangandChang-MingChenandHsing-LungChaoandChun-ShuLinandYu-FuSuandJang-ChunLin",year="2011",month=mar,day="1",doi="http://www.airitilibrary.com/Publication/alDetailedMesh?docid=1023988x-201103-201104160006-201104160006-37-45",language="English",volume="18",pages="37--45",journal="放射治療與腫瘤學",issn="1023-988x",publisher="台灣放射腫瘤學會",number="1",} TY-JOURT1-ComparisonofTreatmentResultsofMalignantAstrocytomaafterpost-opRadiotherapyAloneorpost-opConcurrentChemoradiotherapyplusAdjuvantchemotherapy-ExperienceinTSGHAU-Lin,Kuen-TzeAU-Wu,Ching-JungAU-Jen,Yee-MinAU-Lee,MeeiShyuanAU-Huang,Wen-YenAU-Chen,Chang-MingAU-Chao,Hsing-LungAU-Lin,Chun-ShuAU-Su,Yu-FuAU-Lin,Jang-ChunPY-2011/3/1Y1-2011/3/1N2-Purpose:ToanalyzethetreatmentresultsofmalignantastrocytomaafterradiotherapyaloneorconcurrentchemoradiotherapyplusadjuvantchemotherapyinTSGH.MethodsandMaterials:FromApril2002toDecember2007,weidentified35patientswithdocumented,histologicallyconfirmed,previouslyuntreatedglioblastomamultiforme(GBM)oranaplasticastrocytoma(AA).Theyweretreatedwithsurgicalresectionfollowedbyradiotherapyaloneorchemoradiotherapyinourhospital.Atotalof60Gywasgivenin6weekswith3DconformalRT(3D-CRT).FusionofplanningCTwithMRIwasroutinelyusedtoassisttargetdelineation.Weusedconcomitanttemozolomide(75mg/m^2dailyupto49days)followedbyuptosixcyclesofadjuvanttemozolomide(150to200mg/m^2dailyforfivedays,every28days).Follow-upandsurvivaltimeswerecalculatedfromthedateofdiagnosistothedateoflastcontactordeath.Disease-freesurvival(DFS)andoverallsurvival(OS)werecomputedbyKaplan-Meiermethods.Results:Themedianfollow-upwas19.1months.Atthetimeofanalysis,10patientswerealive,25patientshaddied.Themediansurvivalratewas19.1monthsforallpatients.The3-yearoverallsurvivalrateswere14%and43%inradiotherapyalonearmandCCRTarm,respectively.(p=0.002).The3-yearprogression-freesurvivalrateswere10.6%and13.9%inradiotherapyaloneandCCRTarm,respectively.(p=0.54).IntheAAgroup,theoverallsurvivalrateswere8.7%and67.9%inradiotherapyalonearmandCCRTarm,respectively.(p=0.001).IntheGBMgroup,theoverallsurvivalrateswere16.3%and23.7%inradiotherapyaloneandCCRTarm,respectively.(p=0.261).In-fieldfailurewasthemajorcauseoffailure,among35patients,22(62.8%)patientshadin-fieldfailure.Allpatientscompletedradiotherapycourses.Thirty(86%)patientshadgrade1CNStoxicityand5(14%)patientshadgrade2CNStoxicity.Among21patientswhoreceivedtemozolomide,18patientshadnoobvioussideeffectsduringandafterchemotherapy.Conclusions:AdditionofadjuvantchemotherapywithtemozolomidetoradiotherapyforpatientswithnewlydiagnosedAAandGBMhasstatisticallysignificantsurvivalbenefitespeciallyforpatientsofAAwithtolerabletoxicity.AB-Purpose:ToanalyzethetreatmentresultsofmalignantastrocytomaafterradiotherapyaloneorconcurrentchemoradiotherapyplusadjuvantchemotherapyinTSGH.MethodsandMaterials:FromApril2002toDecember2007,weidentified35patientswithdocumented,histologicallyconfirmed,previouslyuntreatedglioblastomamultiforme(GBM)oranaplasticastrocytoma(AA).Theyweretreatedwithsurgicalresectionfollowedbyradiotherapyaloneorchemoradiotherapyinourhospital.Atotalof60Gywasgivenin6weekswith3DconformalRT(3D-CRT).FusionofplanningCTwithMRIwasroutinelyusedtoassisttargetdelineation.Weusedconcomitanttemozolomide(75mg/m^2dailyupto49days)followedbyuptosixcyclesofadjuvanttemozolomide(150to200mg/m^2dailyforfivedays,every28days).Follow-upandsurvivaltimeswerecalculatedfromthedateofdiagnosistothedateoflastcontactordeath.Disease-freesurvival(DFS)andoverallsurvival(OS)werecomputedbyKaplan-Meiermethods.Results:Themedianfollow-upwas19.1months.Atthetimeofanalysis,10patientswerealive,25patientshaddied.Themediansurvivalratewas19.1monthsforallpatients.The3-yearoverallsurvivalrateswere14%and43%inradiotherapyalonearmandCCRTarm,respectively.(p=0.002).The3-yearprogression-freesurvivalrateswere10.6%and13.9%inradiotherapyaloneandCCRTarm,respectively.(p=0.54).IntheAAgroup,theoverallsurvivalrateswere8.7%and67.9%inradiotherapyalonearmandCCRTarm,respectively.(p=0.001).IntheGBMgroup,theoverallsurvivalrateswere16.3%and23.7%inradiotherapyaloneandCCRTarm,respectively.(p=0.261).In-fieldfailurewasthemajorcauseoffailure,among35patients,22(62.8%)patientshadin-fieldfailure.Allpatientscompletedradiotherapycourses.Thirty(86%)patientshadgrade1CNStoxicityand5(14%)patientshadgrade2CNStoxicity.Among21patientswhoreceivedtemozolomide,18patientshadnoobvioussideeffectsduringandafterchemotherapy.Conclusions:AdditionofadjuvantchemotherapywithtemozolomidetoradiotherapyforpatientswithnewlydiagnosedAAandGBMhasstatisticallysignificantsurvivalbenefitespeciallyforpatientsofAAwithtolerabletoxicity.KW-AnaplasticastrocytomaKW-GlioblastomamultiformeKW-TemozolomideKW-RadiotherapyKW-ChemoradiotherapyKW-ConformalradiationtherapyKW-惡性星狀細胞瘤KW-多形惡性神經膠質瘤KW-帝盟多KW-放射治療KW-同步放射化學治療KW-順形放射治療U2-http://www.airitilibrary.com/Publication/alDetailedMesh?docid=1023988x-201103-201104160006-201104160006-37-45DO-http://www.airitilibrary.com/Publication/alDetailedMesh?docid=1023988x-201103-201104160006-201104160006-37-45M3-ArticleVL-18SP-37EP-45JO-放射治療與腫瘤學JF-放射治療與腫瘤學SN-1023-988xIS-1ER-